Introduction Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options. Due to its invasive nature, current therapies fail to provide long-term survival benefits, leaving the glioblastoma multiforme survival rate distressingly low. Most patients face a median survival of just over a year post-diagnosis. However, the glioblastoma market by...